Market Institute President Charles Sauer has a new article out in Townhall on the State of the Union address and the inclusion of anti-innovation practices like price setting.
Here’s an excerpt.
“When the international community slapped sanctions on Putin’s Russia, many people cheered. Bad things were going to start happening to a bad country.
However, with rampant inflation and a domestic energy sector that had already been attacked by the reckless Biden Administration, the effect on the American economy is likely going to be harmful as well. Now, in defense of the Ukrainian people and greater stability in the world, that harm might be worth it, but the pain that we are all about to experience didn’t have to be this bad. And, looking around at the rest of the Biden agenda – he seems to be using the same playbook and making many similar mistakes.
The public policies that the President announced at Tuesday’s State of the Union will slow innovation and investment – which means that responding to the next emergency will be even harder.
When COVID-19 was unleashed, a vaccine was developed in days. That development is thanks to the fact that in the U.S. we enjoy a robust, competitive research and development economy with strong rule of law to protect innovators. In fact, not just one vaccine was developed, but multiple vaccines. This wasn’t an accident, the founders of our great country understood the benefits of an innovative society – including patents as the only explicit right in the Constitution, and inventors and innovators are an important piece of nation’s history.
The reason for this competitive market comes down to two factors. First, we have patents in the US which entitle the inventor of a new “thing,” in this case a new drug, the exclusive right to that invention for 20 years. Second, the companies that produce these drugs are allowed to price their new drugs and sell them to willing and thankful buyers.
However, in the President’s State of the Union, and other speeches that he has given around the country, the President has called for setting the prices of drugs – like insulin. This idea sounds good on its face for winning short-term political points, but it undercuts the two principles that have made the US the innovative economy that it is by lowering the value of patents – and restricting the ability of pharmaceutical companies to profit.
This lowers the incentive of investors to invest and inventors to invent – which means that the next time the country is facing an emergency – the research and development industry won’t be as robust, it won’t be as prepared, it won’t be as aggressive.
It isn’t just big pharmaceutical companies; this change also harms the small inventor. When the large companies can’t be assured of profits from big breakthroughs, they are less likely to buy innovations from smaller innovators.”